Cyproheptadine Hydrochloride/Prazosin Hydrochloride

盐酸赛庚啶/盐酸哌唑嗪

Report date: 2023/11/29 13:44:55
NME

Base Information

Drug NameCyproheptadine Hydrochloride/Prazosin Hydrochloride
Drug Alias NameCyproheptadine/Prazosin combination therapyCyproheptadine+prazosinPeriactine+AlpressKT110KT-110
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors antagonistsSerotonin 2 (5-HT2) receptor antagonistsAlpha-1a adrenergic receptor antagonists +[6] 
TargetsHistamine receptorAdrenergic receptorsSerotonin 2 (5-HT2) receptor +[7] 
Therapy Area/IndicationsAlcoholism
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsYes Cyproheptadine HydrochloridePrazosin Hydrochloride
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKinnov Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesKinnov Therapeutics
Inactive CompaniesN/A
Active IndicationsAlcoholism
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A